MICHAEL B YAFFE, M.D.
Radiology at Chesbrough Rd, Boston, MA
License number
Massachusetts 151835
Category
Radiology
Type
Surgical Critical Care
Address
Address
1 Chesbrough Rd, Boston, MA 02132
Phone
(617) 452-2103
Professional information
David H. Koch Professor Of Science At Mit
Position:
Lieutenant Colonel - Army Reserve Medical Corps at US Army, David H. Koch Professor of Science at MIT, Staff Physician at Beth Israel Deaconess Medical Center
Location:
Greater Boston Area
Industry:
Research
Work:
US Army
since 2009
-
Lieutenant Colonel - Army Reserve Medical Corps
MIT
- Cambridge, Massachusetts since Sep 2000
-
David H. Koch Professor of Science
Beth Israel Deaconess Medical Center
since 1995
-
Staff Physician
MIT
2003 - May 2009
-
Associate Professor
MIT Center for Cancer Research
2000 - May 2009
-
Associate Professor
Beth Israel Deaconess Medical Center
1996 - 1998
-
Post-doctoral Fellow
University Hospitals of Cleveland
1991 - 1992
-
Resident in Surgery
Beth Israel Deaconess Medical Center
1989 - 1991
-
Intern in Surgery
Education:
Case Western Reserve University School of Medicine 1981 - 1989
M.D., Ph.D. Cornell University 1977 - 1981
Bachelor of Science (B.S.), Materials Science
M.D., Ph.D. Cornell University 1977 - 1981
Bachelor of Science (B.S.), Materials Science
Methods And Compositions For Cancer Treatment Relating To Brca1 Brct Domain Recognition Of Phosphorylated Bach1
US Patent:
2012029, Nov 22, 2012
Filed:
Apr 19, 2012
Appl. No.:
13/451209
Inventors:
Michael B. Yaffe - West Roxbury MA, US
Julie A. Clapperton - London, GB
Isaac A. Manke - Cambridge MA, US
Drew M. Lowery - Cambridge MA, US
Stephen J. Smerdon - London, GB
Lesley F. Haire - London, GB
Julie A. Clapperton - London, GB
Isaac A. Manke - Cambridge MA, US
Drew M. Lowery - Cambridge MA, US
Stephen J. Smerdon - London, GB
Lesley F. Haire - London, GB
International Classification:
G06F 19/16, G06T 17/00, G01N 21/64, C40B 30/04, G01N 33/566, C07K 1/00
US Classification:
506 9, 436501, 530333, 435 792, 703 11, 345419
Abstract:
The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a human BRCT domain-BACH1 phosphopeptide complex.
Methods And Compositions For Cancer Treatment Relating To Brca1 Brct Domain Recognition Of Phosphorylated Bach1
US Patent:
2006005, Mar 9, 2006
Filed:
May 9, 2005
Appl. No.:
11/126022
Inventors:
Michael Yaffe - West Roxbury MA, US
Julie Clapperton - London, GB
Isaac Manke - Cambridge MA, US
Drew Lowery - Cambridge MA, US
Stephen Smerdon - London, GB
Julie Clapperton - London, GB
Isaac Manke - Cambridge MA, US
Drew Lowery - Cambridge MA, US
Stephen Smerdon - London, GB
International Classification:
G06F 19/00
US Classification:
702027000
Abstract:
The present invention relates to compounds (e.g., peptidomimetics and non-peptides) that treat, prevent, or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.
Michael Bruce Yaffe, Boston MA
Specialties:
Surgery, Surgical Critical Care
Work:
Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston, MA 02215
330 Brookline Ave, Boston, MA 02215
Education:
Case Western Reserve University(1989)
Cell-Based Screening Methods
US Patent:
6730492, May 4, 2004
Filed:
Mar 9, 2002
Appl. No.:
10/093945
Inventors:
Michael H. Cardone - Boston MA
Michael Yaffe - Jamaica Plain MA
Michael Yaffe - Jamaica Plain MA
Assignee:
Merrimack Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 148
US Classification:
435 15, 4353201, 435 6, 4352523, 435194, 435 691, 530350
Abstract:
Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
Cell-Based Screening Methods
US Patent:
2003017, Sep 11, 2003
Filed:
Mar 9, 2002
Appl. No.:
10/093840
Inventors:
Michael Cardone - Boston MA, US
Michael Yaffe - Jamaica Plain MA, US
Michael Yaffe - Jamaica Plain MA, US
International Classification:
C12Q001/70, G01N033/53, C12Q001/48
US Classification:
435/005000, 435/007100, 435/015000
Abstract:
Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
Products And Processes For Modulating Peptide-Peptide Binding Domain Interactions
US Patent:
2005019, Sep 8, 2005
Filed:
Nov 14, 2003
Appl. No.:
10/713978
Inventors:
Michael Yaffe - West Roxbury MA, US
Andrew Elia - Boston MA, US
Peter Rellos - Herts, GB
Lewis Cantley - Cambridge MA, US
Stephen Smerdon - London, GB
Isaac Manke - Cambridge MA, US
Andrew Elia - Boston MA, US
Peter Rellos - Herts, GB
Lewis Cantley - Cambridge MA, US
Stephen Smerdon - London, GB
Isaac Manke - Cambridge MA, US
International Classification:
G01N033/53
US Classification:
435007100, 702019000
Abstract:
The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains.
Cell-Based Screening Methods
US Patent:
2003017, Sep 11, 2003
Filed:
Mar 9, 2002
Appl. No.:
10/093838
Inventors:
Michael Cardone - Boston MA, US
Michael Yaffe - Jamaica Plain MA, US
Michael Yaffe - Jamaica Plain MA, US
International Classification:
C12Q001/66, C12N009/12, C07H021/04, C12P021/02, C12N005/06
US Classification:
435/194000, 435/069700, 435/320100, 435/325000, 536/023200
Abstract:
Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
Cell-Based Screening Methods
US Patent:
7083938, Aug 1, 2006
Filed:
Feb 3, 2004
Appl. No.:
10/771035
Inventors:
Michael H. Cardone - Boston MA, US
Michael Yaffe - Jamaica Plain MA, US
Michael Yaffe - Jamaica Plain MA, US
Assignee:
Merrimack Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/48, C12N 9/00, C12P 21/06, C07K 1/00
US Classification:
435 15, 435183, 435 691, 530350
Abstract:
Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
Methods And Compositions For Treating Cellular Proliferative Diseases
US Patent:
2006011, Jun 1, 2006
Filed:
Nov 14, 2005
Appl. No.:
11/273567
Inventors:
Michael Yaffe - West Roxbury MA, US
Isaac Manke - Cambridge MA, US
Hans Reinhardt - Cambridge MA, US
Daniel Lim - Cambridge MA, US
Isaac Manke - Cambridge MA, US
Hans Reinhardt - Cambridge MA, US
Daniel Lim - Cambridge MA, US
International Classification:
A61K 48/00, A61K 38/21, A61K 38/17, A61K 38/09, A61K 31/7072, A61K 31/522, A61K 31/7048, A61K 31/704, A61K 31/513, A61K 31/4745, A61K 31/407, A61K 31/415, A61K 31/19
US Classification:
424085400, 514002000, 514044000, 514015000, 514171000, 514034000, 514283000, 514263310, 514449000, 514575000, 514049000, 514546000, 514027000, 514269000, 514410000, 514406000
Abstract:
The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders.